Artelo Biosciences, Inc. (ARTLW)

0.0197 +0.0080 (+68.38%) At close: 04:00PM EDT

Artelo Biosciences, Inc.

505 Lomas Santa Fe
Suite 160
Solana Beach, CA 92075
United States
858 925 7049
https://www.artelobio.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 6

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Gregory D. Gorgas M.B.A.	President, CEO, CFO, Treasurer, Secretary & Director	742.45k	N/A	1963
Dr. Andrew Yates Ph.D.	Senior VP & Chief Scientific Officer	N/A	N/A	N/A
Dr. Steven D. Reich	Chief Medical Officer	N/A	N/A	1946
Mr. Jason H. Baybutt	Senior Vice President of Finance	N/A	N/A	1972

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for treating breast and prostate cancer, neuropathic and nociceptive pain, and anxiety disorders, including PTSD. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

Corporate governance

Artelo Biosciences, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.